Piramal Invests $2.5m to Expand ADC Capacity in Scotland
Piramal is upgrading its ADC (antibody drug conjugate) manufacturing capacity in response to demand from clients in late phase trials looking to ramp up production.
News & Analysis on Clinical Trial Services & Contract Research And Development
- Home
- APIs (active pharmaceutical ingredients)
- Delivery formulations
- Delivery technologies
- Excipients, raw materials & intermediates
- Processing equipment
- QA/QC
- Regulations
- Tabletting, coating & ancillary equipment
- Analytical testing, QC
- Bulk ingredients
- Contract Manufacturing
- Contract sales & marketing
- Data management
- Drug delivery, formulation
- Fill & finish, packaging
- Medical Devices
- Phase I-II
- Phase III-IV
- Preclinical
- Regulatory affairs
- Supply chain, logistics
- Validation services
- Suppliers